These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 28991670)

  • 21. Biosimilars: how similar?
    Strand V; Cronstein B
    Intern Med J; 2014 Mar; 44(3):218-23. PubMed ID: 24118772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biosimilars: A consideration of the regulations in the United States and European union.
    Daller J
    Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A consistency approach for evaluation of biosimilar products.
    Tsou HH; Chang WJ; Hwang WS; Lai YH
    J Biopharm Stat; 2013; 23(5):1054-66. PubMed ID: 23957515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparability and biosimilarity: considerations for the healthcare provider.
    Lee JF; Litten JB; Grampp G
    Curr Med Res Opin; 2012 Jun; 28(6):1053-8. PubMed ID: 22519391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biosimilars and the European experience: implications for the United States.
    Megerlin F; Lopert R; Taymor K; Trouvin JH
    Health Aff (Millwood); 2013 Oct; 32(10):1803-10. PubMed ID: 24101072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical data and regulatory issues of biosimilar products.
    Stevenson JG
    Am J Manag Care; 2015 Dec; 21(16 Suppl):s320-30. PubMed ID: 26788808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The challenge of follow-on biologics for treatment of multiple sclerosis.
    Reingold SC; Steiner JP; Polman CH; Cohen JA; Freedman MS; Kappos L; Thompson AJ; Wolinsky JS
    Neurology; 2009 Aug; 73(7):552-9. PubMed ID: 19687456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Global regulatory standards for the approval of biosimilars.
    Mounho B; Phillips A; Holcombe K; Grampp G; Lubiniecki T; Mollerup I; Jones C
    Food Drug Law J; 2010; 65(4):819-37, ii-iii. PubMed ID: 24479248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulatory considerations in oncologic biosimilar drug development.
    Macdonald JC; Hartman H; Jacobs IA
    MAbs; 2015; 7(4):653-61. PubMed ID: 25961747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC).
    Fernandes GS; Sternberg C; Lopes G; Chammas R; Gifoni MAC; Gil RA; Araujo DV
    Braz J Med Biol Res; 2018 Jan; 51(3):e7214. PubMed ID: 29340530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biosimilars for the next decade in Latin America: a window of opportunity.
    Bas TG
    Expert Opin Biol Ther; 2023; 23(8):659-669. PubMed ID: 37542714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What are biosimilars and are they important?
    Drug Ther Bull; 2013 May; 51(5):57-60. PubMed ID: 23657197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Developing oncology biosimilars: an essential approach for the future.
    Abraham J
    Semin Oncol; 2013 Dec; 40 Suppl 1():S5-24. PubMed ID: 24267944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists.
    Covic A; Abraham I
    Int Urol Nephrol; 2015 Sep; 47(9):1529-39. PubMed ID: 26223197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The emerging role of biosimilar epoetins in nephrology in the United States.
    Fishbane S; Shah HH
    Am J Kidney Dis; 2015 Apr; 65(4):537-42. PubMed ID: 25582283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The advent of biosimilars for the treatment of diabetes: current status and future directions.
    Polimeni G; Trifirò G; Ingrasciotta Y; Caputi AP
    Acta Diabetol; 2015 Jun; 52(3):423-31. PubMed ID: 25990669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statistical assessment of biosimilar products.
    Chow SC; Liu JP
    J Biopharm Stat; 2010 Jan; 20(1):10-30. PubMed ID: 20077246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Biosimilars versus original biologics. Similarities and differences from development to approval].
    Windisch J
    Z Rheumatol; 2015 Oct; 74(8):672-81. PubMed ID: 26323591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
    Grabowski HG; Guha R; Salgado M
    Health Aff (Millwood); 2014 Jun; 33(6):1048-57. PubMed ID: 24889955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
    Jahnz-Rozyk K; Wiesik-Szewczyk E;
    Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.